Singapore: Developing a precision oncology ecosystem enabled by data

Singapore has been trailblazing data-driven care models through the digitalization of its healthcare system, with a ground-breaking national electronic medical record system.

Ensuring patients can fully derive value from these new models will require a concerted effort to develop and implement pathways focused on enabling tailored approaches to cancer care, helping to build a better future for patients across Singapore by improving both health and economic outcomes.

In 2022, a collaboration between Roche and the Singapore Translational Cancer Consortium (STCC), a nationally coordinated consortium designed to synergise cancer research capabilities, was established to drive adoption of a ‘precision oncology’ care model. The aim is to build a healthcare ecosystem focused on personalisation of cancer care enabled by a national clinico-genomic database, with the connected data infrastructure and workflow necessary for long-term sustainability. 

With opportunities for both short and long-term economic impact, the partnership has the potential to bridge from clinical research to sustainable care delivery, achieved through a more efficient and cost-effective approach to generating and analysing data, and using that data to improve care delivery. This, ultimately, could lead to the availability of more personalised medicines, at a lower cost, lending to greater appeal to establish Singapore as an anchor for industry research and innovation.

With this partnership, the STCC in collaboration with Roche aims to position Singapore as a clinical trial hub within Asia-Pacific, using the adoption of a more personalised care model to advance therapeutics and diagnostics in the region. 

Across Singapore, more patients suitable for molecularly guided (or ‘targeted’) treatment and clinical trials will be identified using comprehensive genomic profiling and recommendations from Molecular Tumour Boards at each participating hospital. Real-world evidence will be generated through analysis of data stored in a national clinico-genomic database, which can be leveraged for research and innovation activities, to improve both health and economic outcomes for more sustainable healthcare delivery. 

See all stories

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeCovid-19Pharma solutionsRoche careersMedia libraryAnnual Report 2023Privacy policyLegal statement